The Conversation (0)
Resverlogix received approval from Health Canada to go forth with a clinical trial for the company’s lead compound apabetalone treating Fabry disease.
Resverlogix (TSX:RVX) received approval from Health Canada to go forth with a clinical trial for the company’s lead compound apabetalone treating Fabry disease.
As quoted in the press release:
Fabry Disease Clinical Trial Summary
This is an open-label, exploratory clinical study to assess the patient safety and effect on key biomarkers of apabetalone in subjects with Fabry disease for up to 16 weeks.
The primary objective of the study is to evaluate the safety and tolerability of apabetalone in patients with Fabry disease. Secondary objectives include evaluating the effect of apabetalone in subjects with Fabry disease as determined by change in key biomarkers including alkaline phosphatase (ALP), high-sensitivity C-reactive protein (hs-CRP), and other well-known markers for chronic kidney disease.
The study population will consist of two cohorts:Cohort 1: Patients with Fabry disease receiving enzyme replacement therapy (ERT).
Cohort 2: Patients with Fabry disease not receiving ERT
Click here to read the full press release.
Source: www.newswire.ca